Katarína Gatialová 🇪🇺🇸🇰🇧🇪

Join @ViatrisEUPolicy and @MedicinesforEU at 16:15 for a panel discussion on access to critical medicines and supply chain solutions with @gloriagheq @anca4health @AdrianMEDSforEU @WalterVanDyck & more 👉 buff.ly/3Yisjyu #EHFG2024

The car of the EU Ambassador to the UK has quite the statement number plate.

🌍🏥 How can we secure equitable futures for all citizens across Europe? At #EHFG2023 @ViatrisEUPolicy & @uoaofficial discussed the urgent need for action in the European periphery w/ @natasha_azzmus @AdrianMEDSforEU & more! 📺 bit.ly/45MnM7s #EHFG2023Rewind

Here’s to wonderful company & discussions at last night’s welcome buffet @GasteinForum! 🍽️🤝🗣️ #EHFG2023

📣 We are happy to announce that the #Viatris #EU Policy website is now live. ℹ️ Visit our page to learn more about our perspectives as a global healthcare company on the issues impacting patient #access to medicines. viatrispolicy.eu

🌍🏥 How can we secure equitable futures for all citizens across Europe? Join @ViatrisEUPolicy and @uoaofficial at #EHFG2023 on 🗓️ 28 Sept to discuss the urgent need for action in the European periphery. Register today 👉 bit.ly/3KnyYzA

We're excited to launch soon our Viatris EU policy website 🎉 This website will help you to: ➡️Get to know Viatris and our presence in Europe. ➡️See what we do to promote equal access to health. ➡️Understand our position on different topics. Countdown begins👀

We're thrilled to share that we are sponsoring a panel hosted by the University of Athens in the #EHFG23. Interested in health disparities in European periphery countries? You cannot miss this session! Stay tuned get to know more 👀 @GasteinForum #Healthiswealth

We are delighted to contribute to and participate in the United Nations General Assembly (UNGA) 2023 across all three of the official high-level meetings (HLMs) on health and several side events! viatris.com/en/UNGA #viaViatris #UNGA2023

We’re back from another productive trip to the @Europarl_EN in Strasbourg! 💡 While there, we discussed how to foster an attractive ecosystem for life sciences innovation throughout the EU ⚕️ Here's how we can boost Europe's attractiveness for healthcare amchameu.eu/node/15848

Yesterday, a delegation of @medicinesforEU met with @DolorsMM, @susanasolisp and Nicolas Gonzales Casares in the @Europarl_EN to discuss challenges and opportunities of the #EUpharmalegislation, and potential solutions to enable patients' access to #medicines.

Today, we're celebrating the @eupatientsforum 20th anniversary 🎉 Supporting the voice of patients and putting them at the center of health discussions is essential to promote the right to health. We are proud to be one of the sponsors of this event💪 #HealthForAll #EPF20

@AckoAnkarberg opening today ´s @sweden2023eu event in Stockholm discussing new legislative landscape for pharmaceuticals in the EU. #eupharmalegislation #medicines

Europe’s life expectancy at birth for men and women has fallen for the second consecutive year, according to @Eurostat data released today, with the figures standing at 82.9 years and 77.2 years, respectively. These figures are now back to rates seen about a decade ago. #COVID19

@medicinesforEU Board is committed to ensuring patients access to essential 💊 whenever and wherever they need. We must secure balanced access, manage inflation📈, prevent shortages & reduce environmental impact🌍.Together, we can make a difference🤝! #EUPharmaStrategy #offpatent

At the event in @SLOVAKIAinEU, @GLOBSEC is highlighting that CEE countries have lower healthcare spending and high out-of-pocket spending, resulting in poorer health outcomes. The #pharmalegislation can provide opportunities to promote equal access to medicines in the EU.

Inflation exposes Slovakia’s already ‘complex’ generics pricing system ift.tt/5r3tUae

Berlin aims to fend off drugs shortages without general prices adjustments ift.tt/3tlLqdv

@DolorsMM @medicinesforEU @AdrianMEDSforEU

The average price of life- saving generics 💊in Spain is around €3.50, but almost 50% of all generics are priced at €1.60 or less hitting the bottom of viability. How are going to build a sustainable future-proof off-patent sector in EU without discussing regulated pricing?